INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Corporate insider
OP

O'Day Daniel Patrick

Director, Chairman & CEOCIK 0001638643

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 4
Max Insider Score27
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise
M—
8,780 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    GILEAD SCIENCES, INC.Director, Chairman & CEO · Dec 30, 2025
5
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise
M
—
8,780 sh
Sep 10, 2026
Sep 11, 2026
traded Sep 10, 2026
+1d
SEC FORM 4

Evidence

11
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Tax withholding
F$613K
4,230 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$895K
6,950 sh
Apr 28, 2026Apr 29, 2026
traded Apr 28, 2026
+1dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$397K
3,050 sh
Apr 28, 2026Apr 29, 2026
traded Apr 28, 2026
+1dSEC FORM 4

Evidence

0
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M—
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$7.63M
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

27
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$15.61M
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

14
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$1.25M
10.0K sh
Dec 29, 2025Dec 30, 2025
traded Dec 29, 2025
+1dSEC FORM 4

Evidence